Department of Neuroscience, Carleton University Ottawa, ON, Canada.
Front Cell Neurosci. 2013 May 10;7:68. doi: 10.3389/fncel.2013.00068. eCollection 2013.
The development of depressive disorders had long been attributed to monoamine variations, and pharmacological treatment strategies likewise focused on methods of altering monoamine availability. However, the limited success achieved by treatments that altered these processes spurred the search for alternative mechanisms and treatments. Here we provide a brief overview concerning a possible role for pro-inflammatory cytokines and growth factors in major depression, as well as the possibility of targeting these factors in treating this disorder. The data suggest that focusing on one or another cytokine or growth factor might be counterproductive, especially as these factors may act sequentially or in parallel in affecting depressive disorders. It is also suggested that cytokines and growth factors might be useful biomarkers for individualized treatments of depressive illnesses.
抑郁障碍的发展长期以来归因于单胺的变化,药理学治疗策略也同样集中在改变单胺可用性的方法上。然而,改变这些过程的治疗方法所取得的有限成功促使人们寻找替代机制和治疗方法。在这里,我们简要概述了促炎细胞因子和生长因子在重度抑郁症中的可能作用,以及针对这些因子治疗该疾病的可能性。数据表明,专注于一种或另一种细胞因子或生长因子可能适得其反,特别是因为这些因子在影响抑郁障碍时可能依次或并行地发挥作用。还提出细胞因子和生长因子可能是抑郁性疾病个体化治疗的有用生物标志物。